Protagonist Therapeutics, Inc. announced the closing of the worldwide collaboration and license agreement for rusfertide with Takeda, a leading values-based, R&D-driven biopharmaceutical company, disclosed on January 31, 2024. Closing of the transaction was contingent on completion of review under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976 in the United States. Protagonist will receive the $300 million upfront payment associated with the transaction in the second quarter of 2024.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
25.29 USD | +0.56% | -3.97% | +11.44% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.44% | 1.47B | |
+2.28% | 42.75B | |
+47.81% | 41.61B | |
+11.85% | 41.34B | |
-12.36% | 26.59B | |
+8.25% | 25.49B | |
-24.16% | 18.12B | |
+29.79% | 12.24B | |
-2.26% | 11.76B | |
+7.59% | 11B |
- Stock Market
- Equities
- PTGX Stock
- News Protagonist Therapeutics, Inc.
- Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda